 By beginning treatment, you've taken a very important step—not only for you, but for those close to you  Enroll in the Here to Help™ Program and get ongoing support that can help you stay motivated as you begin to get your life back on track. Here to Help gives you:
Find out how support can help you:
Getting control of your opioid dependence may be a challenge, but you won't have to face it alone—we're Here to Help. Take care,  866-973-HERE (4373) |
    | ||||||||||||||||||||||||||||
|
Unsubscribe | Privacy
Promise | Terms of Use | Prescribing Information This communication is sponsored by Reckitt Benckiser Pharmaceuticals Inc. and intended for residents of the United States. © 2009 Reckitt Benckiser Pharmaceuticals Inc. SUBOXONE® and SUBUTEX® are registered trademarks of Reckitt Benckiser Pharmaceuticals Inc. ("Reckitt Benckiser") or its affiliated companies. Here to Help™ is a trademark of Reckitt Benckiser Pharmaceuticals Inc. This information in this e-mail is provided for educational and informational purposes only and is not intended as a substitute for direct consultation with a qualified mental health professional.  
Important Safety Information
SUBOXONE® (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets) (CIII) is indicated for the treatment of opioid dependence. It is extremely dangerous to take benzodiazepines or other depressants while taking SUBOXONE. A serious overdose and death may occur if benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol are taken at the same time as SUBOXONE. SUBOXONE has potential for abuse and produces dependence of the opioid type, with a milder withdrawal syndrome than full agonists. Cytolytic hepatitis and hepatitis with jaundice have been observed in the addicted population receiving buprenorphine. Allergic reactions including bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients taking buprenorphine. There are no adequate and well-controlled studies of SUBOXONE (a Category C medication) in pregnancy. Caution should be exercised when driving cars or operating machinery. Always store buprenorphine-containing medications safely and out of the reach and sight of children. Destroy any unused medication appropriately. The most commonly reported adverse events with SUBOXONE include: headache (36%, placebo 22%), withdrawal syndrome (25%, placebo 37%), pain (22%, placebo 19%), insomnia (14%, placebo 16%), nausea (15%, placebo 11%), and constipation (12%, placebo 3%). Please see full Prescribing Information for a complete list. To report an adverse event caused by taking SUBOXONE, please call 1-877-782-6966. You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please see full US Prescribing Information for SUBOXONE. |